EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase III)Randomisierte kontrollierte StudieÄquivalenzstudieOpen Access · CC BY-NC-ND 4.0

Efficacy and Safety of Elagolix Versus Dienogest for Treatment of Moderate‐to‐Severe Endometriosis Pain: A Phase III , Multicentric, Double‐Blind, Active‐Controlled, Non‐Inferiority Study

Sneha Bhoir, Jaldhara Patel, Tushar Palve, Mrinal Kanti Dash, Sweety Saigal, Gourisankar Kamilya, Shalini Srivastava, Kartikbhai Savalia, Tanusree Gupta, Deepa Choudhary, Manohar Rangaswamy, Vidya V Bhatt und 13 weitere

BJOG: An International Journal of Obstetrics & Gynaecology · 2026

DOI: 10.1111/1471-0528.70256 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift BJOG: An International Journal of Obstetrics & Gynaecology, 2026. Verfasst von Sneha Bhoir und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obsterics and Gynaecology, KKasturi Medicare Pvt Ltd, Thane, India. Hauptthemen laut MEDLINE: Nandrolone, Endometriosis, Pelvic Pain, Hydrocarbons, Fluorinated. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sun Pharmaceutical Industries Limited, Sun Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To compare the efficacy, safety and tolerability of elagolix with dienogest in women with moderate‐to‐severe endometriosis‐associated pain.

Design

A multicentre, double‐blind, double‐dummy, randomised, parallel‐group, active‐controlled, non‐inferiority phase III study.

Setting

Nineteen clinical centres across India. Study Population Women (18–49 years) diagnosed with endometriosis and experiencing moderate‐to‐severe pain.

Methods

Participants were randomised (1:1) to receive oral elagolix (150 mg once daily) or dienogest (2 mg once daily) for 24 weeks. Outcome Measures The primary outcome was change in endometriosis‐related pain (Numeric Rating Scale [NRS]) from baseline to Day 85. Secondary outcomes included changes in NRS (Day 169), dysmenorrhoea, non‐menstrual pelvic pain (NMPP) scores (Days 85 and 169), rescue medication use, patient global impression of change (PGIC), adverse events and bone mineral density.

Results

Of 340 patients screened, 230 were randomised (115 per group). At Day 85, both arms showed similar reductions in NRS pain scores with a treatment difference of 0.04 (95% CI: −0.3, 0.37) [ p = 0.9747] demonstrating non‐inferiority as upper 95% CI was below pre‐specified margin of 1.5. At Day 169, both arms showed comparable improvements in overall pain, dysmenorrhoea and NMPP from baseline ( p = 0.9372, p = 0.8884, and p = 0.9616, respectively). Rescue medication use and PGIC were comparable between treatment arms. Adverse event incidence was similar (elagolix: 14.8%; dienogest: 19.1%), with no serious TEAEs or discontinuations. No significant bone mineral density changes were observed.

Conclusions

Elagolix demonstrated non‐inferiority to dienogest with an acceptable safety and tolerability profile, supporting its use in managing endometriosis‐associated pain. Trial Registration ClinicalTrials.gov identifier: CTRI/2023/01/049292

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NandroloneEndometriosisPelvic PainHydrocarbons, FluorinatedPyrimidinesHumansFemaleDouble-Blind MethodAdultMiddle AgedTreatment OutcomeYoung AdultAdolescentPain MeasurementIndia

Stichwörter der Autor:innen

GnRH antagonistdienogestelagolixendometriosis

Substanzen

dienogestNandroloneelagolixHydrocarbons, FluorinatedPyrimidines

Autor:innen und Institutionen

  • Department of Obsterics and Gynaecology, KKasturi Medicare Pvt Ltd, Thane, India.
  • Department of Obsterics and Gynaecology, Pagarav Hospital & ICU, Gandhinagar, India.
  • Cama and Albless Hospital, Mumbai, India.
  • Department of Obsterics and Gynaecology, Sparsh Hospital & Critical Care Pvt Ltd, Bhubaneshwar, India.
  • Department of Obsterics and Gynaecology, Brij Medical Centre Pvt Ltd, Kanpur, India.
  • Department of Gynaecology and Obstetrics, IPGME&R and SSKM Hospital, Kolkata, India.

ORCID-Profile: Dipak Patil

Förderung

  • Sun Pharmaceutical Industries Limited
  • Sun Pharma

Zitieren

APA

Bhoir, S., Patel, J., Palve, T., Dash, M. K., Saigal, S., Kamilya, G., Srivastava, S., Savalia, K., Gupta, T., Choudhary, D., Rangaswamy, M., Bhatt, V. V., Gupta, N., Ponnuru, M., Shah, P., Shetty, A., Saha, S., Quadros, R., Pandit, S., …, & Joglekar, S. (2026). Efficacy and Safety of Elagolix Versus Dienogest for Treatment of Moderate‐to‐Severe Endometriosis Pain: A Phase III , Multicentric, Double‐Blind, Active‐Controlled, Non‐Inferiority Study. BJOG: An International Journal of Obstetrics & Gynaecology. https://doi.org/10.1111/1471-0528.70256

Vancouver

Bhoir S, Patel J, Palve T, Dash MK, Saigal S, Kamilya G, et al. Efficacy and Safety of Elagolix Versus Dienogest for Treatment of Moderate‐to‐Severe Endometriosis Pain: A Phase III , Multicentric, Double‐Blind, Active‐Controlled, Non‐Inferiority Study. BJOG: An International Journal of Obstetrics & Gynaecology. 2026. doi:10.1111/1471-0528.70256

BibTeX
@article{Bhoir2026,
  author = {Bhoir, Sneha and Patel, Jaldhara and Palve, Tushar and Dash, Mrinal Kanti and Saigal, Sweety and Kamilya, Gourisankar and Srivastava, Shalini and Savalia, Kartikbhai and Gupta, Tanusree and Choudhary, Deepa and Rangaswamy, Manohar and Bhatt, Vidya V and Gupta, Neena and Ponnuru, Malathi and Shah, Parul and Shetty, Apurva and Saha, Shruti and Quadros, Reshma and Pandit, Sucheta and Patil, Dipak and Patel, Piyush and Ghadge, Pravin and Lakhwani, Lalit and Mehta, Suyog and Joglekar, Sadhana},
  title = {Efficacy and Safety of Elagolix Versus Dienogest for Treatment of Moderate‐to‐Severe Endometriosis Pain: A Phase III , Multicentric, Double‐Blind, Active‐Controlled, Non‐Inferiority Study},
  journal = {BJOG: An International Journal of Obstetrics & Gynaecology},
  year = {2026},
  doi = {10.1111/1471-0528.70256}
}
Kostenlos starten →